Clinical Trial Update: Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID [Phase 3]

View source ↗

Summary

Phase 3 trial assessing tolerability and safety of IGSC with rHuPH20 in primary immunodeficiency diseases completed with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunodeficiency Diseases

Drugs mentioned

• Immune Globulin Subcutaneous Solution (idgsc with rHuPH20)

Snippet

Sponsor: Baxalta now part of Shire | Conditions: Primary Immunodeficiency Diseases (PID) | Phase 3 | Status: COMPLETED | Results posted: 2016-05-26